STudying Acute exaceRbations and Response: The COPD STARR 2 study

Slides:



Advertisements
Similar presentations
WHAT ABOUT THE IMP? IMP HANDLING FOR THE TRIAL SITE PHARMACY.
Advertisements

Timelines Trust informed June 2007
Chicken Soup for the Busy Coordinator
The Principal Investigator’s Roles and Responsibilities Chicken Soup for the Busy Coordinator (May 2010)
Rare Film Guide Slide Set. Clinical Trial Design for Pirfenidone Study Purpose of Study: To see if the use of pirfenidone decreases the loss of lung function.
Launch Event – 6 th November 2014 Trial Information and Design Isabel Rubie – Trial Manager The NAtional Trial of Tonsillectomy IN Adults: a clinical and.
Maximizing Recruitment in ACST-2. Recruitment to Date Clinical trials require VERY large numbers of patients, because they study MODERATE effects… … therefore.
ROLE OF NURSES IN CLINICAL RESEARCH IN MALAWI OWEN DAIRE BSCN MPH RNM.
Atorvastatin in Factorial with Omega-3 fatty acid Risk Reduction in Diabetes …in an academic collaboration with.
SYNOPSIS OF THE PROTOCOL Title: Pregnancy Associated Breast Cancer (PABC); Prospective Data Registry in Saudi Arabia Sponsor: Oncology Department, King.
Training Module 2: Respondent Eligibility Criteria.
The early use of Antibiotics in at Risk CHildren with InfluEnza Chief Investigator: Dr Kay Wang Senior Trial.
Primary Aim To compare outcomes of participants with symptoms of stable angina or angina equivalent evaluated with an anatomic imaging strategy using CCTA.
Template for study specific training for Intrapartum Research Studies [ Please see guide before using this]
Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.
Collecting data in clinic.  Aim of BADBIR  Definition of Adverse Events  Adverse events in BADBIR  Adverse event recording in hospital case notes.
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group,
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
How To Design a Clinical Trial
INPULSIS® trial design and baseline characteristics
Investigational Devices and Humanitarian Use Devices June 2007.
Indiaclen Short course of Amoxicillin in treatment of Pneumonia (ISCAP) 3 versus 5 days amoxicillin for treatment of non-severe pneumonia in young children:
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Antibiotics in Addition to Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease Johannes M.A. Daniels; Dominic snijders;
Responsibilities of Sponsor, Investigator and Monitor
Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.
JCIA Update (April – May 2011). KFSH&RC Mission JCIA accreditation is designed to create that culture. KFSH&RC provides the highest level of specialized.
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
CLINICAL TRIALS.
Refer to Beds & Herts Breast Cancer Family History Screening service
Wales Primary Care COPD Audit
IMPAACT 2010 Protocol Specifications for Recruitment, Screening, and Enrollment No updates.
HOW TO SCREEN PATIENTS AND BOOK THE BASELINE VISIT APPOINTMENT?
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Acute Exacerbations of COPD
Jessica Case study.
How To Design a Clinical Trial
Responsibilities of Sponsor, Investigator and Monitor
HOW TO ENTER EARLY WITHDRAWAL DATA
Prescribing, preparation and administration of the IMP including maintaining blinding V6.0 17/01/17.
CONDUCTING THE TRIAL AT
Randomisation Process
MAINTAINING THE INVESTIGATOR’S SITE FILE
Treatment of Latent TB Infection (LTBI)
HOW TO CONSENT A PATIENT?
Good Clinical Practice (GCP) requirements for ANODE
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
The authors have no competing interests to declare.
Patient Medical Records
Blood eosinophil count and exacerbation risk in patients with COPD
Refer to Beds & Herts Breast Cancer Family History Screening service
Basics of IRB Approved Advertisements and Subject Recruitment
ARCADIA Coordinator Webinar
HOW TO ENTER BASELINE DATA
HOW TO SCREEN PATIENTS AND BOOK THE BASELINE VISIT APPOINTMENT?
HOW TO CONSENT A PATIENT?
Investigator of Record – Definition
EPIC Tools for Clinical Research
CONDUCTING THE TRIAL AT
Tailored GCP & Trial Specific training
MAINTAINING THE INVESTIGATOR’S STUDY FILE
MITO 26 PHASE II TRIAL ON TRABECTEDIN IN THE TREATMENT OF ADVANCED UTERINE AND OVARIAN CARCINOSARCOMA (CS)
TRTO (Translational Research Trials Office)
EPIC Tools for Clinical Research
SYNOPSIS OF THE PROTOCOL
EPIC Tools for Clinical Research
D94- COPD: EPIDEMIOLOGY AND THERAPY
Nottingham City Care Integrated Respiratory Service and Home Oxygen Service Zoe Styles Senior Physiotherapist.
Khai Hoan Tram, Jane O’Halloran, Rachel Presti, Jeffrey Atkinson
Principal recommendations
Presentation transcript:

STudying Acute exaceRbations and Response: The COPD STARR 2 study

STARR 2 Team Research Nurses – Helen Jeffers & Joanne Davies Contact interested patients (once initial contact has been made by GP surgery) Consent & randomise participants Conduct trial visits Dispense prednisolone/placebo CRF completion/data entry CI – Dr Mona Bafadhel

Trial Summary Current treatment of corticosteroids and antibiotics during an exacerbation = “one size fits all”. Follow on from STARR study which identified eosinophils as a biomarker during exacerbations. STARR 2 is looking at whether an eosinophil- directed therapy to personalise treatment reduces inappropriate and excessive drug therapy. 10 GP surgeries in Thames Valley GPs will be PI for each site

PI Responsibilities The PI has overall responsibility for activity at a site and it is their role to ensure that site staff are suitably trained for responsibilities he/she has delegated at the start and throughout the trial. The safety of participants should be overseen by the responsible PI at site. Before a trial is opened at a site, the PI should complete this training to ensure they have understood the trial and their responsibility as PI for STARR 2. In the event that a PI is off on annual leave, the PI should delegate responsibility to another GP to cover their duties in the interim. Especially to ensure there is cover in the event of an SAE. If a PI leaves the surgery, the trial manager needs to be notified immediately as they will give guidance on how to proceed at site.

Inclusion Criteria Participant is willing and able to give informed consent for participation in the trial. Male or Female, aged 40 years or above. Diagnosed with COPD (FEV1/FVC ratio <0.7). A history of at least 1 exacerbation in the previous 12 months, requiring systematic corticosteroids and/or antibiotics. Current or ex-smoker with at least 10 pack year smoking history. In the opinion of the research staff, is able and willing to comply with all trial requirements.

Exclusion Criteria History of atopic childhood asthma. Current history of primary lung malignancy or active pulmonary TB. Clinically relevant disease or disorder (past or present) Any clinically relevant lung disease, other than COPD considered by the investigator to be the primary diagnosis. An alternative cause for the increase in symptoms of COPD pneumonia pulmonary embolism pneumothorax primary ischaemic event – ST or Non ST elevation myocardial infarct and left ventricular failure

Exclusion Criteria (cont) A known allergy to the IMP (prednisolone), NIMP (doxycycline) or to any of the constituents of the placebo Patients on maintenance corticosteroids (prednisolone, hydrocortisone, fludrocortisone) Known adrenal insufficiency Currently enrolled in another CTIMP trial and receiving intervention as part of the trial. Pregnant and breast-feeding women.

Stable Visit This is a scheduled visit and occurs when the participant is 6 weeks free from an exacerbation. This visit can occur immediately following informed consent or following randomisation at a subsequent later date. All data obtained can be added directly to patient’s record. Spirometry; FeNO; MRC, HADS, VAS & CAT scores

Intervention Overview

Randomisation Procedure Randomisations for STARR 2 will be via RRAMP. This is a web based system that can be accessed from anywhere with an internet connection. The STARR 2 research nurses will perform the randomisations. The PIs at each site will receive notification emails through when a new participant has been randomised at their site. There is no emergency randomisation method.

Emergency Unblinding All emergency unblinding will be at the discretion of the local PI when clinically indicated for the safety of the patient. Emergency unblinding can be performed via RRAMP by the STARR 2 Research Nurses, the PI or the Trial Manager (if required). Non-emergency unblinding can be requested via the RRAMP system and will require approval by the CI.

Where Next? What the research is looking at and how this may influence future practice? Point of care testing Prescribing based on eosinophil count and CRP Personalised exacerbation treatment

Any questions? Contact Details: CI – Prof Mona Bafadhel: mona.bafadhel@ndm.ox.ac.uk Research Nurse – Helen Jeffers: helen.jeffers@ndm.ox.ac.uk Research Nurse – Joanne Davies: joanne.davies@ndm.ox.ac.uk Trial Manager – Hania Piotrowska: hania.piotrowska@ouh.nhs.uk – 01865 225552